HRP20100378T1 - Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti - Google Patents
Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti Download PDFInfo
- Publication number
- HRP20100378T1 HRP20100378T1 HR20100378T HRP20100378T HRP20100378T1 HR P20100378 T1 HRP20100378 T1 HR P20100378T1 HR 20100378 T HR20100378 T HR 20100378T HR P20100378 T HRP20100378 T HR P20100378T HR P20100378 T1 HRP20100378 T1 HR P20100378T1
- Authority
- HR
- Croatia
- Prior art keywords
- triazolo
- pyrazin
- pyrazol
- piperazin
- ylamino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title claims 2
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical class C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 51
- -1 Amide 4-{8-[4-(4-methyl-piperazin-1-yl)-phenylamino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl}-thiophen-2- carboxylic acids Chemical class 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 150000001408 amides Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- BFSRNZLXCZKVNW-UHFFFAOYSA-N 2-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-4,5-dihydrothieno[2,3-c]pyrrol-6-one Chemical compound S1C=2C(=O)NCC=2C=C1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 BFSRNZLXCZKVNW-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- CHQJJYPKXYBSSN-UHFFFAOYSA-N N-[4-(4-tert-butylpiperazin-1-yl)phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 CHQJJYPKXYBSSN-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000000155 isotopic effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- DXISVZIQEPORSC-UHFFFAOYSA-N (4-butan-2-ylpiperazin-1-yl)-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1CN(C(C)CC)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 DXISVZIQEPORSC-UHFFFAOYSA-N 0.000 claims 1
- VBVSWIUDHKAUIO-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1CN(CC)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 VBVSWIUDHKAUIO-UHFFFAOYSA-N 0.000 claims 1
- AGRRXZLTXIRFHF-UHFFFAOYSA-N (4-phenylpiperazin-1-yl)-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC=C1 AGRRXZLTXIRFHF-UHFFFAOYSA-N 0.000 claims 1
- XTOZATPZCUYVPR-UHFFFAOYSA-N (4-piperidin-1-ylpiperidin-1-yl)-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)N(CC1)CCC1N1CCCCC1 XTOZATPZCUYVPR-UHFFFAOYSA-N 0.000 claims 1
- XSDUUIHPTXGMTN-UHFFFAOYSA-N (4-propan-2-ylpiperazin-1-yl)-[3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=C1 XSDUUIHPTXGMTN-UHFFFAOYSA-N 0.000 claims 1
- FFFUXLUPRZEMIL-UHFFFAOYSA-N 1-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]piperazin-2-one Chemical compound O=C1CNCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 FFFUXLUPRZEMIL-UHFFFAOYSA-N 0.000 claims 1
- QDKZNYZQKYAEMW-UHFFFAOYSA-N 1-[5-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 QDKZNYZQKYAEMW-UHFFFAOYSA-N 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- YBUAZHKDDGUHHM-UHFFFAOYSA-N 2,5-dihydropyrrol-1-yl-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)N1CC=CC1 YBUAZHKDDGUHHM-UHFFFAOYSA-N 0.000 claims 1
- HRPXCAHEPGIUMW-UHFFFAOYSA-N 2,6-difluoro-4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)N)=C(F)C=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 HRPXCAHEPGIUMW-UHFFFAOYSA-N 0.000 claims 1
- YLMHOHHWOPOHBH-UHFFFAOYSA-N 2,6-difluoro-4-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC(F)=C(C(N)=O)C(F)=C1 YLMHOHHWOPOHBH-UHFFFAOYSA-N 0.000 claims 1
- CGZZIEITQLQBOG-UHFFFAOYSA-N 2-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-5,6-dihydrofuro[2,3-c]pyrrol-4-one Chemical compound C=1C=2C(=O)NCC=2OC=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 CGZZIEITQLQBOG-UHFFFAOYSA-N 0.000 claims 1
- VKUVJWJZEWKBRP-UHFFFAOYSA-N 2-fluoro-4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)N)=CC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 VKUVJWJZEWKBRP-UHFFFAOYSA-N 0.000 claims 1
- BNNUKUVBEFWNMO-UHFFFAOYSA-N 2-fluoro-4-[8-[4-(4-methylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(N)=O)C(F)=C1 BNNUKUVBEFWNMO-UHFFFAOYSA-N 0.000 claims 1
- VBVIHCRFIFYNSO-UHFFFAOYSA-N 2-methoxy-N-[(6-methylpyridin-3-yl)methyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=C(C(=O)NCC=2C=NC(C)=CC=2)C(OC)=CC=1NC(C1=NC=NN11)=NC=C1C=1C=NNC=1 VBVIHCRFIFYNSO-UHFFFAOYSA-N 0.000 claims 1
- GIAQJIIDNXNNSY-UHFFFAOYSA-N 3,3-dimethyl-5-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2h-isoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2(C)C)C2=C1 GIAQJIIDNXNNSY-UHFFFAOYSA-N 0.000 claims 1
- QVDSFKDOVDIPSJ-UHFFFAOYSA-N 3,6-dihydro-2H-pyridin-1-yl-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)N1CCC=CC1 QVDSFKDOVDIPSJ-UHFFFAOYSA-N 0.000 claims 1
- ZIJWGGAFCXAOPN-UHFFFAOYSA-N 3-[4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=CC(=CC=2)C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=N1 ZIJWGGAFCXAOPN-UHFFFAOYSA-N 0.000 claims 1
- JYBCHEQZETVKRB-UHFFFAOYSA-N 3-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1-benzothiophene-7-carboxamide Chemical compound C=1SC=2C(C(=O)N)=CC=CC=2C=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 JYBCHEQZETVKRB-UHFFFAOYSA-N 0.000 claims 1
- JHOJVWLTDDKOKE-UHFFFAOYSA-N 3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]-N-(pyridin-2-ylmethyl)benzamide Chemical compound C=1C=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=CC=1C(=O)NCC1=CC=CC=N1 JHOJVWLTDDKOKE-UHFFFAOYSA-N 0.000 claims 1
- GZYQVOQCWOVTBW-UHFFFAOYSA-N 3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound NC(=O)C1=CC=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=C1 GZYQVOQCWOVTBW-UHFFFAOYSA-N 0.000 claims 1
- ZSUFWZOCGCTTBU-UHFFFAOYSA-N 3-fluoro-4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound FC1=CC(C(=O)N)=CC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 ZSUFWZOCGCTTBU-UHFFFAOYSA-N 0.000 claims 1
- ZKIPRFSOFNNCMK-UHFFFAOYSA-N 3-fluoro-4-[8-[4-(4-methylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(N)=O)C=C1F ZKIPRFSOFNNCMK-UHFFFAOYSA-N 0.000 claims 1
- BUYLMIPFLKSPIS-UHFFFAOYSA-N 4-[4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(=CC=2)C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 BUYLMIPFLKSPIS-UHFFFAOYSA-N 0.000 claims 1
- QSPAEZUXLKWALT-UHFFFAOYSA-N 4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)N)=NC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 QSPAEZUXLKWALT-UHFFFAOYSA-N 0.000 claims 1
- IUSQIOFMDVXKRJ-UHFFFAOYSA-N 4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 IUSQIOFMDVXKRJ-UHFFFAOYSA-N 0.000 claims 1
- FYSTUPGUTFXHBJ-UHFFFAOYSA-N 4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 FYSTUPGUTFXHBJ-UHFFFAOYSA-N 0.000 claims 1
- SFEDCFUOTZYOEK-UHFFFAOYSA-N 4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 SFEDCFUOTZYOEK-UHFFFAOYSA-N 0.000 claims 1
- WNDKNBCWYSXUPN-UHFFFAOYSA-N 4-[8-(4-piperazin-1-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCNCC3)=NC=2)=C1 WNDKNBCWYSXUPN-UHFFFAOYSA-N 0.000 claims 1
- JPRCFWLPRKUDRL-UHFFFAOYSA-N 4-[8-[(6-benzamidopyridin-3-yl)amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=NC(NC(=O)C=4C=CC=CC=4)=CC=3)=NC=2)=C1 JPRCFWLPRKUDRL-UHFFFAOYSA-N 0.000 claims 1
- ZWOSSIVBFAYQDW-UHFFFAOYSA-N 4-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=NC(=CC=3)N3CCOCC3)=NC=2)=C1 ZWOSSIVBFAYQDW-UHFFFAOYSA-N 0.000 claims 1
- MDGOPRLPIZCNLF-UHFFFAOYSA-N 4-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=NC(=CC=3)N3CCOCC3)=NC=2)=C1 MDGOPRLPIZCNLF-UHFFFAOYSA-N 0.000 claims 1
- RPTBHZFWKPSPBV-UHFFFAOYSA-N 4-[8-[4-(4-methylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]benzamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(N)=O)C=C1 RPTBHZFWKPSPBV-UHFFFAOYSA-N 0.000 claims 1
- ZYVZHYOXPSBOIR-UHFFFAOYSA-N 4-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=CC2=C1CNC2=O ZYVZHYOXPSBOIR-UHFFFAOYSA-N 0.000 claims 1
- HIXXPXGQJXLBEW-UHFFFAOYSA-N 4-[8-[4-(benzylcarbamoyl)-3-methoxyanilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound C=1C=C(C(=O)NCC=2C=CC=CC=2)C(OC)=CC=1NC(C1=NC=NN11)=NC=C1C1=CSC(C(N)=O)=C1 HIXXPXGQJXLBEW-UHFFFAOYSA-N 0.000 claims 1
- AHMHYVIPXVLMLM-UHFFFAOYSA-N 4-[8-[4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)C3CCN(CC(F)(F)F)CC3)=NC=2)=C1 AHMHYVIPXVLMLM-UHFFFAOYSA-N 0.000 claims 1
- VLHDUMDOLLDKJW-UHFFFAOYSA-N 4-[8-[[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=CC2=C1CNC2=O VLHDUMDOLLDKJW-UHFFFAOYSA-N 0.000 claims 1
- NNAAHUUFMAXYRO-UHFFFAOYSA-N 4-[8-[[6-[(2-phenylacetyl)amino]pyridin-3-yl]amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC(C=2N3N=CN=C3C(NC=3C=NC(NC(=O)CC=4C=CC=CC=4)=CC=3)=NC=2)=C1 NNAAHUUFMAXYRO-UHFFFAOYSA-N 0.000 claims 1
- BROKFMHCLYAGQE-UHFFFAOYSA-N 4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]-N-(2-pyridin-4-ylethyl)benzamide Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)NCCC1=CC=NC=C1 BROKFMHCLYAGQE-UHFFFAOYSA-N 0.000 claims 1
- LCRWIORMRJTMFA-UHFFFAOYSA-N 4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]-N-(pyridin-3-ylmethyl)benzamide Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)NCC1=CC=CN=C1 LCRWIORMRJTMFA-UHFFFAOYSA-N 0.000 claims 1
- QTKFTAILYNCRCP-UHFFFAOYSA-N 4-[[5-(2-oxo-1h-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]-n-(pyridin-3-ylmethyl)benzamide Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CC(=O)NC=C3)=CN=2)C=CC=1C(=O)NCC1=CC=CN=C1 QTKFTAILYNCRCP-UHFFFAOYSA-N 0.000 claims 1
- DEFMVBAGGURMRQ-UHFFFAOYSA-N 5-(1,3-benzothiazol-6-yl)-n-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(N=CS2)C2=C1 DEFMVBAGGURMRQ-UHFFFAOYSA-N 0.000 claims 1
- KDVFEVNNBOPRSV-UHFFFAOYSA-N 5-(1-benzothiophen-3-yl)-n-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CSC2=CC=CC=C12 KDVFEVNNBOPRSV-UHFFFAOYSA-N 0.000 claims 1
- RAFCCULIVQNLTP-UHFFFAOYSA-N 5-(1-benzothiophen-3-yl)-n-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CSC2=CC=CC=C12 RAFCCULIVQNLTP-UHFFFAOYSA-N 0.000 claims 1
- UZTYKKLCZXYXSG-CABCVRRESA-N 5-(1H-pyrazol-4-yl)-N-[4-[(2S,5R)-2,4,5-trimethylpiperazin-1-yl]phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C[C@H]1CN(C)[C@H](C)CN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 UZTYKKLCZXYXSG-CABCVRRESA-N 0.000 claims 1
- JFHNYCAHTYRRQB-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-N-[4-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(CC(F)(F)F)CCC1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 JFHNYCAHTYRRQB-UHFFFAOYSA-N 0.000 claims 1
- ZZCXQFFNUVXYKY-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-N-[4-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(CC(F)(F)F)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 ZZCXQFFNUVXYKY-UHFFFAOYSA-N 0.000 claims 1
- NPDVCDFFILSPKI-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-N-[6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(CC(F)(F)F)CCN1C(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 NPDVCDFFILSPKI-UHFFFAOYSA-N 0.000 claims 1
- AQELFIUBLZCPAD-UHFFFAOYSA-N 5-(1h-indazol-5-yl)-n-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(NN=C2)C2=C1 AQELFIUBLZCPAD-UHFFFAOYSA-N 0.000 claims 1
- KVFOKEDTDNGABZ-UHFFFAOYSA-N 5-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C=NN2)C2=C1 KVFOKEDTDNGABZ-UHFFFAOYSA-N 0.000 claims 1
- OAHJYXCKQYZNBR-UHFFFAOYSA-N 5-(1h-indazol-6-yl)-n-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C=NN2)C2=C1 OAHJYXCKQYZNBR-UHFFFAOYSA-N 0.000 claims 1
- XCGSKFSKSMBUSQ-UHFFFAOYSA-N 5-(2-aminopyrimidin-5-yl)-n-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1=NC(N)=NC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 XCGSKFSKSMBUSQ-UHFFFAOYSA-N 0.000 claims 1
- SQLDQQQSDGJHKI-CHQTWICDSA-N 5-[(e,1e)-1-(4-methylidene-1h-pyrazol-5-ylidene)but-2-en-2-yl]-n-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C=1N=C(NC=2C=NC(=CC=2)N2CCN(CC2)C(C)C)C2=NC=NN2C=1/C(=C/C)/C=C1/NN=CC1=C SQLDQQQSDGJHKI-CHQTWICDSA-N 0.000 claims 1
- KHHKVQWMBWTQMJ-UHFFFAOYSA-N 5-[8-(2-chloro-4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C(NC=2C3=NC=NN3C(C=3C=C4CNC(=O)C4=CC=3)=CN=2)C(Cl)=CC=1N1CCOCC1 KHHKVQWMBWTQMJ-UHFFFAOYSA-N 0.000 claims 1
- YVKXXZYGYSLPBB-UHFFFAOYSA-N 5-[8-(2-fluoro-4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C(NC=2C3=NC=NN3C(C=3C=C4CNC(=O)C4=CC=3)=CN=2)C(F)=CC=1N1CCOCC1 YVKXXZYGYSLPBB-UHFFFAOYSA-N 0.000 claims 1
- FLWPFGDKMLWOBV-UHFFFAOYSA-N 5-[8-(4-fluoroanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1=CC(F)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 FLWPFGDKMLWOBV-UHFFFAOYSA-N 0.000 claims 1
- ZDLDULHTZCUMMG-UHFFFAOYSA-N 5-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 ZDLDULHTZCUMMG-UHFFFAOYSA-N 0.000 claims 1
- HFFMARMJJSHTDN-UHFFFAOYSA-N 5-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-3-carboxamide Chemical compound NC(=O)C1=COC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 HFFMARMJJSHTDN-UHFFFAOYSA-N 0.000 claims 1
- HTAHREZOTNAEJN-UHFFFAOYSA-N 5-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC=C1C(N1N=CN=C11)=CN=C1NC1=CC=C(N2CCOCC2)C=C1 HTAHREZOTNAEJN-UHFFFAOYSA-N 0.000 claims 1
- BGKYPWASCWCHMU-UHFFFAOYSA-N 5-[8-(cyclohexylamino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC1CCCCC1 BGKYPWASCWCHMU-UHFFFAOYSA-N 0.000 claims 1
- UVRJZLKUVNLNDN-UHFFFAOYSA-N 5-[8-(oxan-4-ylamino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC1CCOCC1 UVRJZLKUVNLNDN-UHFFFAOYSA-N 0.000 claims 1
- ICKNCAUVHQVTMS-UHFFFAOYSA-N 5-[8-[(2-morpholin-4-ylpyrimidin-5-yl)amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC(C=N1)=CN=C1N1CCOCC1 ICKNCAUVHQVTMS-UHFFFAOYSA-N 0.000 claims 1
- BFAUVRNFXIHEFU-UHFFFAOYSA-N 5-[8-[(6-morpholin-4-ylpyridin-3-yl)amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC(C=N1)=CC=C1N1CCOCC1 BFAUVRNFXIHEFU-UHFFFAOYSA-N 0.000 claims 1
- WUIYMIHYJADQOI-UHFFFAOYSA-N 5-[8-[2-chloro-4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1Cl)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 WUIYMIHYJADQOI-UHFFFAOYSA-N 0.000 claims 1
- ILFSKYBJCHVNJD-UHFFFAOYSA-N 5-[8-[4-(1-propan-2-ylpiperidin-4-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCC1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 ILFSKYBJCHVNJD-UHFFFAOYSA-N 0.000 claims 1
- HBZBAYZNKWTACU-UHFFFAOYSA-N 5-[8-[4-(2-morpholin-4-ylethoxy)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1OCCN1CCOCC1 HBZBAYZNKWTACU-UHFFFAOYSA-N 0.000 claims 1
- LSIOHAGMVUYTCY-UHFFFAOYSA-N 5-[8-[4-(2-oxo-4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound O=C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 LSIOHAGMVUYTCY-UHFFFAOYSA-N 0.000 claims 1
- RAJKOVRGWVJRGX-UHFFFAOYSA-N 5-[8-[4-(2-oxopiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C=1C=C2C(=O)NCC2=CC=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCNCC1=O RAJKOVRGWVJRGX-UHFFFAOYSA-N 0.000 claims 1
- VTESFAODZQAOKN-UHFFFAOYSA-N 5-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 VTESFAODZQAOKN-UHFFFAOYSA-N 0.000 claims 1
- SOSKZUMAFVMCJD-UHFFFAOYSA-N 5-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 SOSKZUMAFVMCJD-UHFFFAOYSA-N 0.000 claims 1
- QWICPTNWZITFIH-UHFFFAOYSA-N 5-[8-[[2-(4-propan-2-ylpiperazin-1-yl)pyrimidin-5-yl]amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(N=C1)=NC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 QWICPTNWZITFIH-UHFFFAOYSA-N 0.000 claims 1
- KUPXYNXWFGYIDC-UHFFFAOYSA-N 5-[8-[[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(C(=O)NC2)C2=C1 KUPXYNXWFGYIDC-UHFFFAOYSA-N 0.000 claims 1
- OLRQTQQXZWALSE-UHFFFAOYSA-N 6-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound C=1C=C2C(=O)NS(=O)(=O)C2=CC=1C(N1N=CN=C11)=CN=C1NC(C=C1)=CC=C1N1CCOCC1 OLRQTQQXZWALSE-UHFFFAOYSA-N 0.000 claims 1
- GNRIPRYGEHPLEE-UHFFFAOYSA-N 6-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=C(CNC2=O)C2=C1 GNRIPRYGEHPLEE-UHFFFAOYSA-N 0.000 claims 1
- OGPDZYDHCXSOGK-UHFFFAOYSA-N 7-fluoro-5-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-2,3-dihydroisoindol-1-one Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C(C=C1F)=CC2=C1C(=O)NC2 OGPDZYDHCXSOGK-UHFFFAOYSA-N 0.000 claims 1
- MTSRYHYGIQXQMX-UHFFFAOYSA-N N,N-diethyl-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=C1 MTSRYHYGIQXQMX-UHFFFAOYSA-N 0.000 claims 1
- YFJMVYXVCJHALM-UHFFFAOYSA-N N-(1-methoxybutan-2-yl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC(COC)CC)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 YFJMVYXVCJHALM-UHFFFAOYSA-N 0.000 claims 1
- RRHNHWZSMNRGDX-UHFFFAOYSA-N N-(2-hydroxyethyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 RRHNHWZSMNRGDX-UHFFFAOYSA-N 0.000 claims 1
- PAAIFMTUVCLKQC-UHFFFAOYSA-N N-(2-methoxyethyl)-N-methyl-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)N(C)CCOC)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 PAAIFMTUVCLKQC-UHFFFAOYSA-N 0.000 claims 1
- AKVMWXGPLVFCEI-UHFFFAOYSA-N N-(2-methylpropyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCC(C)C)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 AKVMWXGPLVFCEI-UHFFFAOYSA-N 0.000 claims 1
- LXHGRBBZPPHGGU-UHFFFAOYSA-N N-(2-methylsulfanylethyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCSC)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 LXHGRBBZPPHGGU-UHFFFAOYSA-N 0.000 claims 1
- WLARYAYYWFBBOV-UHFFFAOYSA-N N-(4-piperazin-1-ylphenyl)-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 WLARYAYYWFBBOV-UHFFFAOYSA-N 0.000 claims 1
- RYOMLAGHZHSREA-UHFFFAOYSA-N N-(cyclohexylmethyl)-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=CC=1C(=O)NCC1CCCCC1 RYOMLAGHZHSREA-UHFFFAOYSA-N 0.000 claims 1
- MVEUFYRLTOZSJT-UHFFFAOYSA-N N-(cyclopropylmethyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)NCC1CC1 MVEUFYRLTOZSJT-UHFFFAOYSA-N 0.000 claims 1
- HZLPDXPHNYIARB-UHFFFAOYSA-N N-(oxolan-2-ylmethyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)NCC1CCCO1 HZLPDXPHNYIARB-UHFFFAOYSA-N 0.000 claims 1
- DGACUWHSLZOGAZ-UHFFFAOYSA-N N-[(1-ethylpyrrolidin-2-yl)methyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound CCN1CCCC1CNC(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 DGACUWHSLZOGAZ-UHFFFAOYSA-N 0.000 claims 1
- SLTAWZFGJNRSMG-UHFFFAOYSA-N N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound O1C(C)(C)OCC1CNC(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 SLTAWZFGJNRSMG-UHFFFAOYSA-N 0.000 claims 1
- LAXGDSVMTVKGEB-JOCHJYFZSA-N N-[(3R)-1-benzylpyrrolidin-3-yl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C([C@H](C1)NC(=O)C=2C=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CN1CC1=CC=CC=C1 LAXGDSVMTVKGEB-JOCHJYFZSA-N 0.000 claims 1
- IHQUHWZSQCNJBO-UHFFFAOYSA-N N-[(4-hydroxyphenyl)methyl]-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(O)=CC=C1CNC(=O)C1=CC=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=C1 IHQUHWZSQCNJBO-UHFFFAOYSA-N 0.000 claims 1
- FPBFRXZIBLPGJN-UHFFFAOYSA-N N-[2-(4-hydroxyphenyl)ethyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(O)=CC=C1CCNC(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 FPBFRXZIBLPGJN-UHFFFAOYSA-N 0.000 claims 1
- GSPOMBOIVYFWKH-UHFFFAOYSA-N N-[2-[di(propan-2-yl)amino]ethyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCN(C(C)C)C(C)C)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 GSPOMBOIVYFWKH-UHFFFAOYSA-N 0.000 claims 1
- IFKYZJQUHFJSSN-UHFFFAOYSA-N N-[4-(2-morpholin-4-ylethoxy)phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1OCCN1CCOCC1 IFKYZJQUHFJSSN-UHFFFAOYSA-N 0.000 claims 1
- LTADIOIOIONVLW-UHFFFAOYSA-N N-[4-(4-cyclopropylpiperazin-1-yl)phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CC1N1CCN(C=2C=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CC1 LTADIOIOIONVLW-UHFFFAOYSA-N 0.000 claims 1
- BNUAGQIURUKXFB-UHFFFAOYSA-N N-[4-(4-methylpiperazin-1-yl)phenyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 BNUAGQIURUKXFB-UHFFFAOYSA-N 0.000 claims 1
- NJSQMHVXSQTDIR-UHFFFAOYSA-N N-[4-(4-methylpiperazin-1-yl)phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 NJSQMHVXSQTDIR-UHFFFAOYSA-N 0.000 claims 1
- KEJPHZROOKODRB-UHFFFAOYSA-N N-[4-(4-methylpiperazin-1-yl)phenyl]-5-(5-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=C(C)NN=C1 KEJPHZROOKODRB-UHFFFAOYSA-N 0.000 claims 1
- MGRBMXPGSUXSTD-UHFFFAOYSA-N N-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 MGRBMXPGSUXSTD-UHFFFAOYSA-N 0.000 claims 1
- SJFCALIVDFEXCP-UHFFFAOYSA-N N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C=2C=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CCN1CC1CC1 SJFCALIVDFEXCP-UHFFFAOYSA-N 0.000 claims 1
- SRKUNLZTJIAOGZ-UHFFFAOYSA-N N-[5-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]pyridin-2-yl]benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C=1C=NNC=1 SRKUNLZTJIAOGZ-UHFFFAOYSA-N 0.000 claims 1
- KERZSNOOXAGUFL-UHFFFAOYSA-N N-[6-(4-cyclopropylpiperazin-1-yl)pyridin-3-yl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CC1N1CCN(C=2N=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CC1 KERZSNOOXAGUFL-UHFFFAOYSA-N 0.000 claims 1
- JINMLVRMKSGVRV-UHFFFAOYSA-N N-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)C)CCN1C(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 JINMLVRMKSGVRV-UHFFFAOYSA-N 0.000 claims 1
- FCYIPZNUCTWQFY-UHFFFAOYSA-N N-[6-[4-(cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl]-5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C=2N=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CCN1CC1CC1 FCYIPZNUCTWQFY-UHFFFAOYSA-N 0.000 claims 1
- DGACUWHSLZOGAZ-SFHVURJKSA-N N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 DGACUWHSLZOGAZ-SFHVURJKSA-N 0.000 claims 1
- MIRIRWWYQHEKPE-UHFFFAOYSA-N N-benzyl-2-methoxy-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=C(C(=O)NCC=2C=CC=CC=2)C(OC)=CC=1NC(C1=NC=NN11)=NC=C1C=1C=NNC=1 MIRIRWWYQHEKPE-UHFFFAOYSA-N 0.000 claims 1
- GBIAFQRZAYQVBC-UHFFFAOYSA-N N-benzyl-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=CC=1C(=O)NCC1=CC=CC=C1 GBIAFQRZAYQVBC-UHFFFAOYSA-N 0.000 claims 1
- IKEUUXDJMMATCV-UHFFFAOYSA-N N-benzyl-N-methyl-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C=1C=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=CC=1C(=O)N(C)CC1=CC=CC=C1 IKEUUXDJMMATCV-UHFFFAOYSA-N 0.000 claims 1
- RPBFPZSBRGQZAF-UHFFFAOYSA-N N-ethyl-3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound CCNC(=O)C1=CC=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=C1 RPBFPZSBRGQZAF-UHFFFAOYSA-N 0.000 claims 1
- MRMRRGWJZIPTEQ-UHFFFAOYSA-N N-ethyl-N-(2-methoxyethyl)-4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzamide Chemical compound C1=CC(C(=O)N(CCOC)CC)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 MRMRRGWJZIPTEQ-UHFFFAOYSA-N 0.000 claims 1
- FGJJUTFVNJSGHQ-UHFFFAOYSA-N N-methyl-1-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzoyl]piperidine-4-carboxamide Chemical class C1CC(C(=O)NC)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 FGJJUTFVNJSGHQ-UHFFFAOYSA-N 0.000 claims 1
- NYBGGMPLCJTBCY-UHFFFAOYSA-N N-methyl-N-[1-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzoyl]pyrrolidin-3-yl]acetamide Chemical compound C1C(N(C)C(C)=O)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 NYBGGMPLCJTBCY-UHFFFAOYSA-N 0.000 claims 1
- AVAQBDJGLMVHMR-UHFFFAOYSA-N N-propan-2-yl-2-[4-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]benzoyl]piperazin-1-yl]acetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 AVAQBDJGLMVHMR-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 1
- JFDPEWDADGRRQZ-UHFFFAOYSA-N [2-morpholin-4-yl-5-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanol Chemical compound C=1C=C(N2CCOCC2)C(CO)=CC=1NC(C1=NC=NN11)=NC=C1C=1C=NNC=1 JFDPEWDADGRRQZ-UHFFFAOYSA-N 0.000 claims 1
- SSPDVDXYRRZJBK-UHFFFAOYSA-N [3-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]-pyrrolidin-1-ylmethanone Chemical compound C=1C=CC(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)=CC=1C(=O)N1CCCC1 SSPDVDXYRRZJBK-UHFFFAOYSA-N 0.000 claims 1
- IFMOEGNAPRSVHB-UHFFFAOYSA-N [4-(2-ethoxyethyl)piperazin-1-yl]-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1CN(CCOCC)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 IFMOEGNAPRSVHB-UHFFFAOYSA-N 0.000 claims 1
- RZKJJLFMOSCVCC-UHFFFAOYSA-N [4-(2-methoxyethyl)piperazin-1-yl]-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1CN(CCOC)CCN1C(=O)C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 RZKJJLFMOSCVCC-UHFFFAOYSA-N 0.000 claims 1
- XXXRYBDZRYYDSC-UHFFFAOYSA-N [4-[(4-fluorophenyl)methyl]piperazin-1-yl]-[4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]methanone Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C=CC(NC=3C4=NC=NN4C(C4=CNN=C4)=CN=3)=CC=2)CC1 XXXRYBDZRYYDSC-UHFFFAOYSA-N 0.000 claims 1
- NFPDZRYLXOILPI-UHFFFAOYSA-N [4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1H-pyrazol-5-yl]methanol Chemical compound N1N=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1CO NFPDZRYLXOILPI-UHFFFAOYSA-N 0.000 claims 1
- CPICEHFVWBSXJW-UHFFFAOYSA-N [4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]pyridin-2-yl]methanol Chemical compound C1=NC(CO)=CC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 CPICEHFVWBSXJW-UHFFFAOYSA-N 0.000 claims 1
- XMGJRIGZLBBPSS-UHFFFAOYSA-N [4-[8-[4-(4-propan-2-ylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]pyridin-2-yl]methanol Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=NC(CO)=C1 XMGJRIGZLBBPSS-UHFFFAOYSA-N 0.000 claims 1
- WIWYXIDDANSIFL-UHFFFAOYSA-N [4-[8-[[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]amino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]pyridin-2-yl]methanol Chemical compound C1CN(C(C)C)CCN1C(N=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=NC(CO)=C1 WIWYXIDDANSIFL-UHFFFAOYSA-N 0.000 claims 1
- CVSBUKOCITYUCO-UHFFFAOYSA-N [4-[[5-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl]amino]phenyl]-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound C=1C=C(NC=2C3=NC=NN3C(C3=CNN=C3)=CN=2)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC=N1 CVSBUKOCITYUCO-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- WSPYBPVYCFYIRM-UHFFFAOYSA-N chembl1956687 Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CNN=C1 WSPYBPVYCFYIRM-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- VSHZLKVKHKMKFB-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)-5-(1h-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CC=NN1 VSHZLKVKHKMKFB-UHFFFAOYSA-N 0.000 claims 1
- PBERAIPVANFQPF-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)-5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CSC=C1 PBERAIPVANFQPF-UHFFFAOYSA-N 0.000 claims 1
- ZJKDVULACFEGOT-UHFFFAOYSA-N n-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]-5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyrazin-8-amine Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=CSC=C1 ZJKDVULACFEGOT-UHFFFAOYSA-N 0.000 claims 1
- BDKKNNARTAMORY-UHFFFAOYSA-N n-methyl-4-[8-(4-morpholin-4-ylanilino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)NC)=NC(C=2N3N=CN=C3C(NC=3C=CC(=CC=3)N3CCOCC3)=NC=2)=C1 BDKKNNARTAMORY-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003216 pyrazines Chemical class 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- YAFOJTVLHTUFQV-UHFFFAOYSA-N triazolo[1,5-a]pyrazine Chemical class C1=CN=CC2=CN=NN21 YAFOJTVLHTUFQV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80355206P | 2006-05-31 | 2006-05-31 | |
| US93176307P | 2007-05-25 | 2007-05-25 | |
| US93184407P | 2007-05-25 | 2007-05-25 | |
| US93176407P | 2007-05-25 | 2007-05-25 | |
| US93210007P | 2007-05-29 | 2007-05-29 | |
| PCT/EP2007/055246 WO2007138072A2 (en) | 2006-05-31 | 2007-05-30 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100378T1 true HRP20100378T1 (hr) | 2010-08-31 |
Family
ID=38618932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100378T HRP20100378T1 (hr) | 2006-05-31 | 2010-07-06 | Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7501411B2 (pt) |
| JP (1) | JP2009538877A (pt) |
| KR (1) | KR20090026288A (pt) |
| AT (1) | ATE465164T1 (pt) |
| AU (1) | AU2007267121A1 (pt) |
| BR (1) | BRPI0712531A2 (pt) |
| CA (1) | CA2653506A1 (pt) |
| CR (1) | CR10458A (pt) |
| DE (1) | DE602007006010D1 (pt) |
| DK (1) | DK2029602T3 (pt) |
| EA (1) | EA200870592A1 (pt) |
| EC (1) | ECSP088923A (pt) |
| HR (1) | HRP20100378T1 (pt) |
| IL (1) | IL195033A0 (pt) |
| MX (1) | MX2008015057A (pt) |
| NI (1) | NI200800299A (pt) |
| NO (1) | NO20084703L (pt) |
| NZ (1) | NZ573015A (pt) |
| PT (1) | PT2029602E (pt) |
| WO (1) | WO2007138072A2 (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2379308C2 (ru) | 2004-04-02 | 2010-01-20 | Оси Фармасьютикалз, Инк. | 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| DK2029602T3 (da) * | 2006-05-31 | 2010-08-09 | Galapagos Nv | Triazolopyrazinforbindelser, der kan anvendes til behandling af degenerative og inflammatoriske sygdomme |
| WO2008065198A1 (en) | 2006-12-01 | 2008-06-05 | Galapagos N.V. | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US8133895B2 (en) * | 2007-05-10 | 2012-03-13 | Janssen Pharmaceutica N.V. | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| DE102008035209A1 (de) | 2008-07-29 | 2010-02-04 | Bayer Schering Pharma Aktiengesellschaft | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| DE102007060172A1 (de) | 2007-12-13 | 2009-06-25 | Bayer Healthcare Ag | Triazolotriazine und Triazolopyrazine und ihre Verwendung |
| CL2009001064A1 (es) * | 2008-05-07 | 2009-10-09 | Galapagos Nv | Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide. |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| BRPI1016245A2 (pt) | 2009-04-20 | 2015-09-01 | Osi Pharmaceuticals Llc | Preparação de c-pirazina-metilaminas. |
| EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
| TW201120043A (en) * | 2009-11-05 | 2011-06-16 | Galapagos Nv | Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| TW201200518A (en) * | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| MA38654B1 (fr) | 2013-06-11 | 2018-11-30 | Bayer Pharma AG | Dérivés de type promédicament de triazolopyridines substituées |
| CN105339370B (zh) * | 2013-06-19 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎症性疾病的化合物和及其药物组合物 |
| EP3089972B1 (de) | 2014-01-03 | 2018-05-16 | Bayer Animal Health GmbH | Neue pyrazolyl-heteroarylamide als schädlingsbekämpfungsmittel |
| EP3137454A1 (en) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| SG11201710694YA (en) | 2015-06-22 | 2018-01-30 | Sumitomo Dainippon Pharma Co Ltd | Bicyclic heterocyclic amide derivative |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| US20180194769A1 (en) | 2015-07-06 | 2018-07-12 | Rodin Therapeutics, Inc. | Hetero-halo inhibitors of histone deacetylase |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| TWI806832B (zh) | 2016-07-12 | 2023-07-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| SI3570834T1 (sl) | 2017-01-11 | 2022-05-31 | Alkermes, Inc. | Biciklični inhibitorji histonske deacetilaze |
| CN110446709B (zh) * | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN109206357A (zh) * | 2017-07-04 | 2019-01-15 | 浙江九洲药业股份有限公司 | 一种格列齐特中间体的通式化合物及其制备方法和应用 |
| HUE058799T2 (hu) | 2017-08-07 | 2022-09-28 | Alkermes Inc | Hiszton-deacetiláz biciklusos inhibitorai |
| RU2020115095A (ru) | 2017-10-12 | 2021-11-12 | Революшн Медсинз, Инк. | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| IL303087B1 (en) | 2018-02-27 | 2024-08-01 | Incyte Corp | Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors |
| CN108379583B (zh) * | 2018-03-27 | 2021-08-17 | 北京大学 | 一种肿瘤转移药物治疗的靶标及其应用 |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN114945598B (zh) * | 2020-02-27 | 2023-12-01 | 世延生医股份有限公司 | 基质金属蛋白酶1的单克隆抗体、其检测试剂盒及其检测方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
| NZ518439A (en) | 1999-10-08 | 2003-10-31 | Gruenenthal Chemie | Bicyclic imidazo-3-yl-amine derivatives |
| KR20020038804A (ko) | 1999-10-08 | 2002-05-23 | 파퀘스, 파우쓰-베르구스 | 6원 환이 치환되어 있는 2환식 이미다조-3-일-아민 유도체 |
| EP1218383B1 (de) | 1999-10-08 | 2008-11-05 | Grünenthal GmbH | Bicyclische imidazo-5-yl-aminderivate |
| DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
| NO20003636A (no) | 2000-07-14 | 2001-11-26 | Zopa As | Fremgangsmåte og anordning for kjøling av produkter i et transportsystem |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20020132823A1 (en) | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
| US20040102455A1 (en) * | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| CN100537571C (zh) * | 2002-04-19 | 2009-09-09 | 细胞基因组公司 | 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法 |
| AU2003272476B2 (en) * | 2002-09-23 | 2007-07-05 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| WO2004072080A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| AU2004282219C1 (en) * | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
| WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| DE602005013085D1 (de) | 2004-06-09 | 2009-04-16 | Oncalis Ag | Proteinkinaseinhibitoren |
| JP4935357B2 (ja) | 2004-11-08 | 2012-05-23 | Ｍｓｄ株式会社 | 新規縮環イミダゾール誘導体 |
| NZ555681A (en) | 2004-11-10 | 2009-08-28 | Cgi Pharmaceuticals Inc | Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| US20060149535A1 (en) * | 2004-12-30 | 2006-07-06 | Lg Electronics Inc. | Method for controlling speed of audio signals |
| WO2006086545A2 (en) | 2005-02-08 | 2006-08-17 | Robert W Desimone | Method to identify novel therapeutics |
| CA2601628C (en) | 2005-03-10 | 2014-05-13 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| KR20080074963A (ko) * | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
| TW200803863A (en) * | 2005-11-10 | 2008-01-16 | Schering Corp | Method for inhibiting protein kinases |
| AR057959A1 (es) | 2005-12-01 | 2007-12-26 | Elan Pharm Inc | 5-pirazolpiperidinas-(sustituidas) |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| DK2029602T3 (da) * | 2006-05-31 | 2010-08-09 | Galapagos Nv | Triazolopyrazinforbindelser, der kan anvendes til behandling af degenerative og inflammatoriske sygdomme |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
-
2007
- 2007-05-30 DK DK07729660.6T patent/DK2029602T3/da active
- 2007-05-30 CA CA002653506A patent/CA2653506A1/en not_active Abandoned
- 2007-05-30 PT PT07729660T patent/PT2029602E/pt unknown
- 2007-05-30 MX MX2008015057A patent/MX2008015057A/es active IP Right Grant
- 2007-05-30 AT AT07729660T patent/ATE465164T1/de active
- 2007-05-30 NZ NZ573015A patent/NZ573015A/en not_active IP Right Cessation
- 2007-05-30 EA EA200870592A patent/EA200870592A1/ru unknown
- 2007-05-30 AU AU2007267121A patent/AU2007267121A1/en not_active Abandoned
- 2007-05-30 US US11/809,294 patent/US7501411B2/en not_active Expired - Fee Related
- 2007-05-30 DE DE602007006010T patent/DE602007006010D1/de active Active
- 2007-05-30 KR KR1020087030751A patent/KR20090026288A/ko not_active Application Discontinuation
- 2007-05-30 BR BRPI0712531-3A patent/BRPI0712531A2/pt not_active IP Right Cessation
- 2007-05-30 WO PCT/EP2007/055246 patent/WO2007138072A2/en active Application Filing
- 2007-05-30 JP JP2009512585A patent/JP2009538877A/ja not_active Abandoned
-
2008
- 2008-10-30 IL IL195033A patent/IL195033A0/en unknown
- 2008-11-10 NO NO20084703A patent/NO20084703L/no not_active Application Discontinuation
- 2008-11-20 NI NI200800299A patent/NI200800299A/es unknown
- 2008-11-25 CR CR10458A patent/CR10458A/es unknown
- 2008-11-28 EC EC2008008923A patent/ECSP088923A/es unknown
-
2009
- 2009-03-08 US US12/399,979 patent/US7915256B2/en not_active Expired - Fee Related
-
2010
- 2010-07-06 HR HR20100378T patent/HRP20100378T1/hr unknown
-
2011
- 2011-01-09 US US12/987,129 patent/US20110178067A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7501411B2 (en) | 2009-03-10 |
| DE602007006010D1 (de) | 2010-06-02 |
| NO20084703L (no) | 2009-02-19 |
| NZ573015A (en) | 2010-11-26 |
| US20110178067A1 (en) | 2011-07-21 |
| US20080090818A1 (en) | 2008-04-17 |
| BRPI0712531A2 (pt) | 2012-12-25 |
| MX2008015057A (es) | 2008-12-10 |
| EA200870592A1 (ru) | 2009-08-28 |
| JP2009538877A (ja) | 2009-11-12 |
| NI200800299A (es) | 2010-05-25 |
| CA2653506A1 (en) | 2007-12-06 |
| IL195033A0 (en) | 2009-08-03 |
| CR10458A (es) | 2009-02-26 |
| ECSP088923A (es) | 2009-01-30 |
| PT2029602E (pt) | 2010-07-08 |
| DK2029602T3 (da) | 2010-08-09 |
| ATE465164T1 (de) | 2010-05-15 |
| WO2007138072A3 (en) | 2008-02-14 |
| US20100298300A1 (en) | 2010-11-25 |
| AU2007267121A1 (en) | 2007-12-06 |
| WO2007138072A2 (en) | 2007-12-06 |
| KR20090026288A (ko) | 2009-03-12 |
| US7915256B2 (en) | 2011-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100378T1 (hr) | Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti | |
| JP2009538877A5 (pt) | ||
| US9963462B2 (en) | Sepiapterin reductase inhibitors | |
| RU2412192C2 (ru) | Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2 | |
| US8163759B2 (en) | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | |
| CN104470924B (zh) | 作为tnf活性调节剂的咪唑并吡嗪衍生物 | |
| ES2585806T3 (es) | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina | |
| RU2014154397A (ru) | Соединения тетрагидропиразолопиримидина | |
| JP5323095B2 (ja) | ピロロ［２，３−ｄ］ピリミジンおよびそのチロシンキナーゼ阻害剤としての使用 | |
| ES2294189T3 (es) | Derivados de pirazolopirimidinona que tienen accion inhibidora de pde7. | |
| JP2021506858A5 (pt) | ||
| AU2006305104A1 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists | |
| US8952004B2 (en) | CXCR3 receptor antagonists | |
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| JP2016102118A (ja) | オレキシン受容体調節因子としての縮合複素環式化合物 | |
| HRP20130958T1 (hr) | Supstituirani derivati sulfonamida | |
| RU2010118018A (ru) | Хиральные цис-имидазолины | |
| JP2010524984A5 (pt) | ||
| US20100305091A1 (en) | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
| RU2007100136A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2006134021A (ru) | Производные гетероарил-конденсированного пиразола | |
| JP2011225604A (ja) | ピラゾール誘導体 | |
| RU2005127335A (ru) | Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ | |
| RU2007102429A (ru) | Производные пиримидиномочевины в качестве ингибиторов киназ | |
| BR112014031731B1 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos |